tafluprost, 209860-87-7

Articles:

PubMed:	Changes in Ocular Surface Characteristics after Switching from Benzalkonium Chloride-Preserved Latanoprost to Preservative-Free Tafluprost or Benzalkonium Chloride-Preserved Tafluprost.
PubMed:	The signs of ocular-surface disorders after switching from latanoprost to tafluprost/timolol fixed combination: a prospective study.
PubMed:	Long term safety and tolerability of Tafluprost 0.0015% vs Timolol 0.1% preservative-free in ocular hypertensive and in primary open-angle glaucoma patients: a cross sectional study.
PubMed:	Effects of pre-surgical administration of prostaglandin analogs on the outcome of trabeculectomy.
PubMed:	[Assessing the added benefit of new ophthalmic drugs : Which additional insights can be extracted from the early benefit assessment?]
PubMed:	Retinal Blood Flow Velocity Change in Parafoveal Capillary after Topical Tafluprost Treatment in Eyes with Primary Open-angle Glaucoma.
PubMed:	Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma and ocular hypertension: results of an open-label observational study.
PubMed:	Prospective Observational Post-Marketing Study of Tafluprost for Glaucoma and Ocular Hypertension: Effectiveness and Treatment Persistence.
PubMed:	Blood Pressure Elevation Associated with Topical Prostaglandin F2α Analogs: An Analysis of the Different Spontaneous Adverse Event Report Databases.
PubMed:	Efficacy and tolerability of preservative-free 0.0015% tafluprost in glaucoma patients: a prospective crossover study.
PubMed:	A Novel Convergent Synthesis of the Potent Antiglaucoma Agent Tafluprost.
PubMed:	Fixed combination of travoprost and timolol maleate reduces intraocular pressure in Japanese patients with primary open-angle glaucoma or ocular hypertension: analysis by prostaglandin analogue.
PubMed:	Impact of prostaglandin glaucoma drops on platelet-activating factor action: an in vitro study.
PubMed:	24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monotherapy.
PubMed:	Analysis of the effects of preservative-free tafluprost on the tear proteome.
PubMed:	Rh(I)-Catalyzed 1,4-Conjugate Addition of Alkenylboronic Acids to a Cyclopentenone Useful for the Synthesis of Prostaglandins.
PubMed:	Comparison study of intraocular pressure reduction efficacy and safety between latanoprost and tafluprost in Japanese with normal-tension glaucoma.
PubMed:	Prospective Observational Post-marketing Study of Tafluprost 0.0015%/Timolol 0.5% Combination Ophthalmic Solution for Glaucoma and Ocular Hypertension: Short-Term Efficacy and Safety.
PubMed:	Advantages of Efficacy and Safety of Fixed-Dose Tafluprost/Timolol Combination Over Fixed-Dose Latanoprost/Timolol Combination.
PubMed:	Ocular Tolerability of Preservative-Free Tafluprost and Latanoprost: in vitro and in vivo Comparative Study.
PubMed:	Preservative-free tafluprost in the treatment of open-angle glaucoma or ocular hypertension in India: a phase III clinical trial.
PubMed:	Long-term topical application of preservative-free prostaglandin analogues evokes macrophage infiltration in the ocular adnexa.
PubMed:	Long-term assessment of prostaglandin analogs and timolol fixed combinations vs prostaglandin analogs monotherapy.
PubMed:	Development of Novel RP-HPLC Method for Separation and Estimation of Critical Geometric Isomer and Other Related Impurities of Tafluprost Drug Substance and Identification of Major Degradation Compounds by Using LC-MS.
PubMed:	Tafluprost Ophthalmic Solution 0.0015 %: A Review in Glaucoma and Ocular Hypertension.
PubMed:	Preservative-free tafluprost/timolol fixed combination: a new opportunity in the treatment of glaucoma.
PubMed:	Pediatric Glaucoma: Pharmacotherapeutic Options.
PubMed:	Prostaglandins in the eye: Function, expression, and roles in glaucoma.
PubMed:	Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials.
PubMed:	Bimatoprost, latanoprost, and tafluprost induce differential expression of matrix metalloproteinases and tissue inhibitor of metalloproteinases.
PubMed:	Association between glaucoma eye drops and hyperemia.
PubMed:	Effects of prostaglandin analogs on blood flow velocity and resistance in the ophthalmic artery of rabbits.
PubMed:	Effect of preservative-free tafluprost on intraocular pressure, pupil diameter, and anterior segment structures in normal canine eyes.
PubMed:	New drugs and preparations for open-angle glaucoma in adults.
PubMed:	Nonresponders to Prostaglandin Analogs Among Normal-Tension Glaucoma Patients.
PubMed:	Comparison of Ocular Pulse Amplitude Lowering Effects of Preservative-Free Tafluprost and Preservative-Free Dorzolamide-Timolol Fixed Combination Eyedrops.
PubMed:	Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis.
PubMed:	Tafluprost/Timolol: A Review in Open-Angle Glaucoma or Ocular Hypertension.
PubMed:	Fixed Combination of Travoprost and Timolol Maleate Reduces Intraocular Pressure in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Prospective Multicenter Open-Label Study.
PubMed:	Twenty-four-hour efficacy of preservative-free tafluprost for open-angle glaucoma patients, assessed by home intraocular pressure (Icare-ONE) and blood-pressure monitoring.
PubMed:	Pharmacokinetics, Efficacy, and Safety of the Preservative-free Fixed Combination of Tafluprost 0.0015% and Timolol 0.5% in Healthy Volunteers: A Phase I Comparison vs. the Corresponding Preservative-free Monotherapies.
PubMed:	Comparison of Ocular Pulse Amplitude-Lowering Effects of Tafluprost and Latanoprost by Dynamic Contour Tonometry.
PubMed:	Benefits of Tafluprost and Timolol Fixed-Dose Combination for the Treatment of Glaucoma Are Confirmed by Studies on Experimental Animal Models.
PubMed:	In Vivo Effects of Preservative-free and Preserved Prostaglandin Analogs: Mouse Ocular Surface Study.
PubMed:	In vitro Effects of Prostaglandin Analogs on Cultured Astrocytes Obtained from the Lamina Cribrosa.
PubMed:	The Impact of Glaucoma Medications on Corneal Wound Healing.
PubMed:	Effects of Four Formulations of Prostaglandin Analogs on Eye Surface Cells. A Comparative Study.
PubMed:	[Randomized parallel group study of 0.0015% tafluprost ophthalmic solution in patients with primary open-angle glaucoma or ocular hypertension (comparison with 0.005% latanoprost ophthalmic solution)].
PubMed:	A 1-year randomized study of the clinical and confocal effects of tafluprost and latanoprost in newly diagnosed glaucoma patients.
PubMed:	[Tafluprost--a novel prostaglandin F2alpha analogue].
PubMed:	Comparison of the toxicity profile of benzalkonium chloride-preserved tafluprost and SofZia-preserved travoprost applied to the ocular surface.
PubMed:	Safety and tolerability of the tafluprost/timolol fixed combination for the treatment of glaucoma.
PubMed:	Excipients of preservative-free latanoprost induced inflammatory response and cytotoxicity in immortalized human HCE-2 corneal epithelial cells.
PubMed:	A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components.
PubMed:	Latanoprost in the treatment of glaucoma.
PubMed:	The circadian changes of intraocular pressure and ocular perfusion pressure after tafluprost compared with travoprost in normal tension glaucoma.
PubMed:	Intraocular pressure decrease with preservative-free fixed and unfixed combination of tafluprost and timolol in pseudoexfoliative glaucoma.
PubMed:	Comparison of the ocular surface changes following the use of two different prostaglandin F2α analogues containing benzalkonium chloride or polyquad in rabbit eyes.
PubMed:	Efficacy of preservative-free tafluprost in patients with normal-tension glaucoma previously treated with latanoprost.
PubMed:	Fixed-dose combination of tafluprost and timolol in the treatment of open-angle glaucoma and ocular hypertension: comparison with other fixed-combination products.
PubMed:	Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension.
PubMed:	Efficacy and safety of tafluprost 0.0015% and timolol maleate 0.5% fixed combination in patients with ocular hypertension or open-angle glaucoma.
PubMed:	Efficacy of intravitreal dexamethasone implant for prostaglandin-induced refractory pseudophakic cystoid macular edema: case report and review of the literature.
PubMed:	Mechanisms of benzalkonium chloride toxicity in a human trabecular meshwork cell line and the protective role of preservative-free tafluprost.
PubMed:	Efficacy, safety, and tolerability of preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5% versus concomitant use of the ingredients.
PubMed:	Prospective observational post-marketing study of tafluprost for glaucoma and ocular hypertension: short-term efficacy and safety.
PubMed:	Comparison of corneal safety and intraocular pressure-lowering effect of tafluprost ophthalmic solution with other prostaglandin ophthalmic solutions.
PubMed:	Ocular surface cytotoxicity and safety evaluation of tafluprost, a recently developed anti-glaucoma prostaglandin analog.
PubMed:	Activation of the prostanoid FP receptor inhibits adipogenesis leading to deepening of the upper eyelid sulcus in prostaglandin-associated periorbitopathy.
PubMed:	OCT evaluation of neuroprotective effects of tafluprost on retinal injury after intravitreal injection of endothelin-1 in the rat eye.
PubMed:	Incidence of deepening of the upper eyelid sulcus on treatment with a tafluprost ophthalmic solution.
PubMed:	Efficacy and tolerability of preservative-free tafluprost 0.0015% in Korean patients with glaucoma.
PubMed:	In vitro effects of preservative-free and preserved prostaglandin analogs on primary cultured human conjunctival fibroblast cells.
PubMed:	Safety and Efficacy of Benzalkonium Chloride-optimized Tafluprost in Japanese Glaucoma Patients With Existing Superficial Punctate Keratitis.
PubMed:	Urrets- Zavalia Syndrome after glaucoma filtration device implantation.
PubMed:	Eyelash growth induced by topical prostaglandin analogues, bimatoprost, tafluprost, travoprost, and latanoprost in rabbits.
PubMed:	Effect of preservative-free tafluprost on keratocytes, sub-basal nerves, and endothelium: a single-blind one-year confocal study on naïve or treated glaucoma and hypertensive patients versus a control group.
PubMed:	Subtenon triamcinolone injection for postoperative cystoid macular edema associated with tafluprost.
PubMed:	Incidence of deepening of upper eyelid sulcus after topical use of tafluprost ophthalmic solution in Japanese patients.
PubMed:	Relative efficacy and safety of preservative-free latanoprost (T2345) for the treatment of open-angle glaucoma and ocular hypertension: an adjusted Indirect comparison meta-analysis of randomized clinical trials.
PubMed:	Effects of tafluprost treatment for 3 years in patients with normal-tension glaucoma.
PubMed:	A study of the association between patterns of eye drop prescription and medication usage in glaucoma subjects.
PubMed:	[Tafluprost (Saflutan) ophthalmic use].
PubMed:	Equilibrium binding interactions between lotrafilcon a soft contact lenses and the two prostaglandin antiglaucoma drugs bimatoprost and tafluprost.
PubMed:	Preservative-free tafluprost in the treatment of naive patients with glaucoma and ocular hypertension.
PubMed:	Effect of tafluprost 0.0015% on central corneal thickness in patients with primary open-angle glaucoma.
PubMed:	Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension.
PubMed:	Short- and long-term corneal vascular effects of tafluprost eye drops.
PubMed:	Conjunctival goblet cells density and preservative-free tafluprost therapy for glaucoma: an in vivo confocal microscopy and impression cytology study.
PubMed:	Effect of topical tafluprost on optic nerve head blood flow in patients with myopic disc type.
PubMed:	New drug update: 2012.
PubMed:	Safety comparison of additives in antiglaucoma prostaglandin (PG) analog ophthalmic formulations.
PubMed:	Tear clearance and ocular symptoms in patients treated with preservative-free prostaglandins.
PubMed:	Therapeutic uses of prostaglandin F(2α) analogues in ocular disease and novel synthetic strategies.
PubMed:	New drugs 2013, Part I.
PubMed:	Tafluprost once daily for treatment of elevated intraocular pressure in patients with open-angle glaucoma.
PubMed:	[Efficacy and tolerability of preservative-free tafluprost 0.0015 % in the treatment of glaucoma and ocular hypertension].
PubMed:	Tafluprost: the first preservative-free prostaglandin to treat open-angle glaucoma and ocular hypertension.
PubMed:	Acute effects of glaucoma medications and benzalkonium chloride on pre-adipocyte proliferation and adipocyte cytotoxicity in vitro.
PubMed:	Corneal epithelial cell viability following exposure to ophthalmic solutions containing preservatives and/or antihypertensive agents.
PubMed:	A randomized crossover study comparing tafluprost 0.0015% with travoprost 0.004% in patients with normal-tension glaucoma [corrected].
PubMed:	The effects of prostaglandin analogues on intracellular Ca2+ in ciliary arteries of wild-type and prostanoid receptor-deficient mice.
PubMed:	Adverse periocular reactions to five types of prostaglandin analogs.
PubMed:	Cell viability score as an integrated indicator for cytotoxicity of benzalkonium chloride-containing antiglaucoma eyedrops.
PubMed:	Deepening of the upper eyelid sulcus caused by 5 types of prostaglandin analogs.
PubMed:	Effects of AFP-172 on COX-2-induced angiogenic activities on human umbilical vein endothelial cells.
PubMed:	Clobazam, ezogabine, and tafluprost.
PubMed:	Toxicity evaluation of antiglaucoma drugs using stratified human cultivated corneal epithelial sheets.
PubMed:	Efficacy and ocular surface tolerability of preservative-free tafluprost 0.0015%: a 6-month, single-blind, observational study on naïve ocular hypertension or glaucoma patients.
PubMed:	Comparison of efficacy of four prostaglandin analogues by bilateral treatment in healthy subjects.
PubMed:	Differential pharmacology and clinical utility of preservative-free tafluprost in the treatment of ocular hypertension and glaucoma.
PubMed:	A prospective study evaluating IOP changes after switching from a therapy with prostaglandin eye drops containing preservatives to nonpreserved tafluprost in glaucoma patients.
PubMed:	Drug metabolite heterogeneity in cultured single cells profiled by pico-trapping direct mass spectrometry.
PubMed:	Tafluprost (Zioptan) - a new topical prostaglandin for glaucoma.
PubMed:	Conjunctiva-associated lymphoid tissue (CALT) reactions to antiglaucoma prostaglandins with or without BAK-preservative in rabbit acute toxicity study.
PubMed:	Spanish multicenter tafluprost tolerability study.
PubMed:	FDA approves glaucoma treatment.
PubMed:	Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension.
PubMed:	Effects of preservative-free tafluprost on tear film osmolarity, tolerability, and intraocular pressure in previously treated patients with open-angle glaucoma.
PubMed:	In vitro study of antiadipogenic profile of latanoprost, travoprost, bimatoprost, and tafluprost in human orbital preadiopocytes.
PubMed:	The cytotoxic effects of preserved and preservative-free prostaglandin analogs on human corneal and conjunctival epithelium in vitro and the distribution of benzalkonium chloride homologs in ocular surface tissues in vivo.
PubMed:	Tafluprost for glaucoma.
PubMed:	Balancing efficacy and tolerability of prostaglandin analogues and prostaglandin-timolol fixed combinations in primary open-angle glaucoma.
PubMed:	Efficacy and safety of tafluprost in normal-tension glaucoma with intraocular pressure of 16 mmHg or less.
PubMed:	Tafluprost: a novel prostaglandin analog for treatment of glaucoma.
PubMed:	Neuroprotective effects of prostaglandin analogues on retinal ganglion cell death independent of intraocular pressure reduction.
PubMed:	Preservative-free tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension.
PubMed:	Switching patients from preserved prostaglandin-analog monotherapy to preservative-free tafluprost.
PubMed:	Metabolism and ocular tissue distribution of an antiglaucoma prostanoid, tafluprost, after ocular instillation to monkeys.
PubMed:	Toxicological evaluation of preservative-containing and preservative-free topical prostaglandin analogues on a three-dimensional-reconstituted corneal epithelium system.
PubMed:	Ocular hypotensive effect of tafluprost in latanoprost low-responder cynomolgus monkeys.
PubMed:	Use of an adult rat retinal explant model for screening of potential retinal ganglion cell neuroprotective therapies.
PubMed:	Gateways to clinical trials.
PubMed:	Tafluprost for the reduction of interocular pressure in open angle glaucoma and ocular hypertension.
PubMed:	Diurnal IOP-lowering efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertension.
PubMed:	Safety and tolerability of tafluprost in treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension.
PubMed:	Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells.
PubMed:	Effects of prostaglandin F(2α) analogues on endothelin-1-induced impairment of rabbit ocular blood flow: comparison among tafluprost, travoprost, and latanoprost.
PubMed:	Cytotoxicity of prostaglandin analog eye drops preserved with benzalkonium chloride in multiple corneoconjunctival cell lines.
PubMed:	Twenty-four-hour ocular hypotensive effects of 0.0015% tafluprost and 0.005% latanoprost in healthy subjects.
PubMed:	A review of preserved and preservative-free prostaglandin analogues for the treatment of open-angle glaucoma and ocular hypertension.
PubMed:	In vitro toxicity of topical ocular prostaglandin analogs and preservatives on corneal epithelial cells.
PubMed:	IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma.
PubMed:	Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.
PubMed:	[Intraocular pressure lowering effect of 0.0015% tafluprost as compared to placebo in patients with normal tension glaucoma: randomized, double-blind, multicenter, phase III study].
PubMed:	[Optimization of benzalkonium chloride concentration in 0.0015% tafluprost ophthalmic solution from the points of ocular surface safety and preservative efficacy].
PubMed:	Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study.
PubMed:	Clinical appraisal of tafluprost in the reduction of elevated intraocular pressure (IOP) in open-angle glaucoma and ocular hypertension.
PubMed:	Effects of topical phenylephrine and tafluprost on optic nerve head circulation in monkeys with unilateral experimental glaucoma.
PubMed:	Effects of repeated administrations of tafluprost, latanoprost, and travoprost on optic nerve head blood flow in conscious normal rabbits.
PubMed:	A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of Tafluprost compared with latanoprost.
PubMed:	[New developments in glaucoma medical treatment].
PubMed:	Ocular hypotensive effects of anti-glaucoma agents in mice.
PubMed:	[Receptors involved in the mechanism of action of topical prostaglandines].
PubMed:	Tafluprost protects rat retinal ganglion cells from apoptosis in vitro and in vivo.
PubMed:	Disposition and metabolism of a novel prostanoid antiglaucoma medication, tafluprost, following ocular administration to rats.
PubMed:	Gateways to clinical trials.
PubMed:	Adjunctive use of tafluprost with timolol provides additive effects for reduction of intraocular pressure in patients with glaucoma.
PubMed:	[Glaucoma--strategy of treatment].
PubMed:	Corneal penetration into rabbit aqueous humor is comparable between preserved and preservative-free tafluprost.
PubMed:	Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis.
PubMed:	Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers.
PubMed:	In search of improved prostaglandin treatment for glaucoma.
PubMed:	Short-term effects of topical tafluprost on retinal blood flow in cats.
PubMed:	Tafluprost, a new potent prostanoid receptor agonist: a dose-response study on pharmacodynamics and tolerability in healthy volunteers.
PubMed:	Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride.
PubMed:	Relaxing effect and mechanism of tafluprost on isolated rabbit ciliary arteries.
PubMed:	In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line.
PubMed:	A comparative, placebo-controlled study of prostanoid fluoroprostaglandin-receptor agonists tafluprost and latanoprost in healthy males.
PubMed:	The IOP-lowering effects and mechanism of action of tafluprost in prostanoid receptor-deficient mice.
PubMed:	Prostanoids in the therapy of glaucoma.
PubMed:	Prostaglandin analogues and mouse intraocular pressure: effects of tafluprost, latanoprost, travoprost, and unoprostone, considering 24-hour variation.
PubMed:	Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug.
PubMed:	New fluoroprostaglandin F(2alpha) derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agents.